The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global generic injectables market reached a value of US$ 33.82 Billion in 2020. Looking forward, IMARC Group expects the market to exhibit strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D cycle is cheaper and shorter. Unlike branded drug manufacturers who spend millions of dollars on R&D and marketing, generic drug manufacturers do not require such investments. Moreover, the number of competitors in the generic injectables market is lower as compared to oral generics, resulting in limited price erosion and significantly higher profit margins.
Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global generic injectables market, along with forecasts at the global and regional level from 2021-2026. Our report has categorized the market based on therapeutic area, container and distribution channel.
Breakup by Therapeutic Area:
The report has segmented the market on the basis of therapeutic area as oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular and others. Currently, the oncology segment accounts for the majority of the market share.
Breakup by Container:
The report has segmented the market on the basis of container covering vials, ampoules, premix and prefilled syringes.
Breakup by Distribution Channel:
The report has segmented the market on the basis of distribution channels covering hospitals and retail pharmacy stores. Among these, hospitals account for the largest market share.
On a regional-basis, the report covers North America, Europe, Asia, Latin America, and Middle East and Africa. North America represents the largest region, accounting for more than a half of the global market.
The report has also analysed the competitive landscape of the market with some of the key players being
This report provides a deep insight into the global generic injectables industry covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the global generic injectables industry in any manner.
|Base Year of the Analysis||2020|
|Segment Coverage||Therapeutic Area, Container, Distribution Channel, Region|
|Region Covered||Asia, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 2999
Corporate License: US$ 3499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at